Alzheimer mechanisms and therapeutic strategies

Cell

Volumn 148, Issue 6, 2012, Pages 1204-1222

  Huang, Yadong ^a,b   Mucke, Lennart ^a,b  

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR; MEMANTINE; METHYLENE BLUE; TAU PROTEIN;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DNA POLYMORPHISM; DRUG TARGETING; EPIGENETICS; GABAERGIC SYSTEM; GENETIC ANALYSIS; HUMAN; INTERNEURON; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 84863337843     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2012.02.040     Document Type: Review

References (202)

1. Y. Andrews-Zwilling, N. Bien-Ly, Q. Xu, G. Li, A. Bernardo, S.Y. Yoon, D. Zwilling, T.X. Yan, L. Chen, and Y. Huang Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice J. Neurosci. 30 2010 13707 13717
2. K.H. Ashe, and K.R. Zahs Probing the biology of Alzheimer's disease in mice Neuron 66 2010 631 645
3. A.A. Asuni, A. Boutajangout, D. Quartermain, and E.M. Sigurdsson Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements J. Neurosci. 27 2007 9115 9129
4. V717F) transgenic mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. USA 96 1999 15233 15238
5. K.R. Bales, F. Liu, S. Wu, S. Lin, D. Koger, C. DeLong, J.C. Hansen, P.M. Sullivan, and S.M. Paul Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice J. Neurosci. 29 2009 6771 6779
6. C. Ballatore, V.M.-Y. Lee, and J.Q. Trojanowski Tau-mediated neurodegeneration in Alzheimer's disease and related disorders Nat. Rev. Neurosci. 8 2007 663 672
7. S.R. Bareggi, M. Franceschi, L. Bonini, L. Zecca, and S. Smirne Decreased CSF concentrations of homovanillic acid and gamma-aminobutyric acid in Alzheimer's disease. Age- or disease-related modifications? Arch. Neurol. 39 1982 709 712
8. D.E. Barnes, and K. Yaffe The projected effect of risk factor reduction on Alzheimer's disease prevalence Lancet Neurol. 10 2011 819 828
9. R.J. Bateman, P.S. Aisen, B. De Strooper, N.C. Fox, C.A. Lemere, J.M. Ringman, S. Salloway, R.A. Sperling, M. Windisch, and C. Xiong Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease Alzheimers Res. Ther. 3 2011 1
10. I. Benilova, E. Karran, and B. De Strooper The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes Nat. Neurosci. 15 2012 349 357
11. D.J. Berlau, M.M. Corrada, E. Head, and C.H. Kawas APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old Neurology 72 2009 829 834
12. A.W. Bero, P. Yan, J.H. Roh, J.R. Cirrito, F.R. Stewart, M.E. Raichle, J.M. Lee, and D.M. Holtzman Neuronal activity regulates the regional vulnerability to amyloid-β deposition Nat. Neurosci. 14 2011 750 756
13. L. Bertram, C.M. Lill, and R.E. Tanzi The genetics of Alzheimer disease: back to the future Neuron 68 2010 270 281
14. I. Bezprozvanny The rise and fall of Dimebon Drug News Perspect. 23 2010 518 523
15. N. Bien-Ly, Y. Andrews-Zwilling, Q. Xu, A. Bernardo, C. Wang, and Y. Huang C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-β (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice Proc. Natl. Acad. Sci. USA 108 2011 4236 4241
16. N. Bien-Ly, A.K. Gillespie, D. Walker, S.Y. Yoon, and Y. Huang Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice J. Neurosci. 32 2012 10.1523/jneurosci.0033-12.2012
17. J. Bousquet, J.M. Anto, P.J. Sterk, I.M. Adcock, K.F. Chung, J. Roca, A. Agusti, C. Brightling, A. Cambon-Thomsen, and A. Cesario Systems medicine and integrated care to combat chronic noncommunicable diseases Genome Med. 3 2011 43
18. H. Braak, and K. Del Tredici Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 121 2011 589 595
19. H. Braak, D.R. Thal, E. Ghebremedhin, and K. Del Tredici Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years J. Neuropathol. Exp. Neurol. 70 2011 960 969
20. W.J. Brecht, F.M. Harris, S. Chang, I. Tesseur, G.-Q. Yu, Q. Xu, J. Dee Fish, T. Wyss-Coray, M. Buttini, and L. Mucke Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice J. Neurosci. 24 2004 2527 2534
21. K.J. Brennand, A. Simone, J. Jou, C. Gelboin-Burkhart, N. Tran, S. Sangar, Y. Li, Y. Mu, G. Chen, and D. Yu Modelling schizophrenia using human induced pluripotent stem cells Nature 473 2011 221 225
22. J. Brodbeck, J. McGuire, Z. Liu, A. Meyer-Franke, M.E. Balestra, D.E. Jeong, M. Pleiss, C. McComas, F. Hess, and D. Witter Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors J. Biol. Chem. 286 2011 17217 17226
23. N. Brouwers, K. Sleegers, S. Engelborghs, V. Bogaerts, S. Serneels, K. Kamali, E. Corsmit, E. De Leenheir, J.J. Martin, and P.P. De Deyn Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease Brain 129 2006 2984 2991
24. K.R. Brunden, J.Q. Trojanowski, and V.M. Lee Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies Nat. Rev. Drug Discov. 8 2009 783 793
25. K.R. Brunden, B. Zhang, J. Carroll, Y. Yao, J.S. Potuzak, A.M. Hogan, M. Iba, M.J. James, S.X. Xie, and C. Ballatore Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy J. Neurosci. 30 2010 13861 13866
26. G. Bu Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy Nat. Rev. Neurosci. 10 2009 333 344
27. -/- mice: isoform-specific effects on neurodegeneration J. Neurosci. 19 1999 4867 4880
28. M. Buttini, G.-Q. Yu, K. Shockley, Y. Huang, B. Jones, E. Masliah, M. Mallory, T. Yeo, F.M. Longo, and L. Mucke Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid β peptides but not on plaque formation J. Neurosci. 22 2002 10539 10548
29. M. Buttini, E. Masliah, G.Q. Yu, J.J. Palop, S. Chang, A. Bernardo, C. Lin, T. Wyss-Coray, Y. Huang, and L. Mucke Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice Am. J. Pathol. 177 2010 563 569
30. S. Camandola, and M.P. Mattson Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease Biochim. Biophys. Acta 1813 2011 965 973
31. D. Campion, C. Dumanchin, D. Hannequin, B. Dubois, S. Belliard, M. Puel, C. Thomas-Anterion, A. Michon, C. Martin, and F. Charbonnier Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum Am. J. Hum. Genet. 65 1999 664 670
32. R.J. Caselli, A.C. Dueck, D. Osborne, M.N. Sabbagh, D.J. Connor, G.L. Ahern, L.C. Baxter, S.Z. Rapcsak, J. Shi, and B.K. Woodruff Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect N. Engl. J. Med. 361 2009 255 263
33. R.J. Caselli, A.C. Dueck, D.E. Locke, M.N. Sabbagh, G.L. Ahern, S.Z. Rapcsak, L.C. Baxter, R. Yaari, B.K. Woodruff, and C. Hoffman-Snyder Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes Neurology 76 2011 1078 1084
34. J.M. Castellano, J. Kim, F.R. Stewart, H. Jiang, R.B. Demattos, B.W. Patterson, A.M. Fagan, J.C. Morris, K.G. Mawuenyega, and C. Cruchaga Human apoE isoforms differentially regulate brain amyloid-{beta} peptide clearance Sci. Transl. Med. 3 2011 89ra57
35. S. Chang, T. ran Ma, R.D. Miranda, M.E. Balestra, R.W. Mahley, and Y. Huang Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity Proc. Natl. Acad. Sci. USA 102 2005 18694 18699
36. Y. Chen, M.S. Durakoglugil, X. Xian, and J. Herz ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling Proc. Natl. Acad. Sci. USA 107 2010 12011 12016
37. H.K. Chen, Z. Liu, A. Meyer-Franke, J. Brodbeck, R.D. Miranda, J.G. McGuire, M.A. Pleiss, Z.S. Ji, M.E. Balestra, and D.W. Walker Small molecule structure correctors abolish detrimental effects of apolipoprotein e4 in cultured neurons J. Biol. Chem. 287 2012 5253 5266
38. J.S. Cheng, D.B. Dubal, D.H. Kim, J. Legleiter, I.H. Cheng, G.Q. Yu, I. Tesseur, T. Wyss-Coray, P. Bonaldo, and L. Mucke Collagen VI protects neurons against Abeta toxicity Nat. Neurosci. 12 2009 119 121
39. J. Chin, J.J. Palop, G.-Q. Yu, N. Kojima, E. Masliah, and L. Mucke Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice J. Neurosci. 24 2004 4692 4697
40. J. Chin, C.M. Massaro, J.J. Palop, M.T. Thwin, G.Q. Yu, N. Bien-Ly, A. Bender, and L. Mucke Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease J. Neurosci. 27 2007 2727 2733
41. L. Chouliaras, B.P. Rutten, G. Kenis, O. Peerbooms, P.J. Visser, F. Verhey, J. van Os, H.W. Steinbusch, and D.L. van den Hove Epigenetic regulation in the pathophysiology of Alzheimer's disease Prog. Neurobiol. 90 2010 498 510
42. M. Cissé, B. Halabisky, J.A. Harris, N. Devidze, D.B. Dubal, B. Sun, A. Orr, G. Lotz, D.H. Kim, and P. Hamto Reversing EphB2 depletion rescues cognitive functions in Alzheimer model Nature 469 2011 47 52
43. M. Citron Alzheimer's disease: strategies for disease modification Nat. Rev. Drug Discov. 9 2010 387 398
44. E. Cohen, J.F. Paulsson, P. Blinder, T. Burstyn-Cohen, D. Du, G. Estepa, A. Adame, H.M. Pham, M. Holzenberger, and J.W. Kelly Reduced IGF-1 signaling delays age-associated proteotoxicity in mice Cell 139 2009 1157 1169
45. T.J. Cohen, J.L. Guo, D.E. Hurtado, L.K. Kwong, I.P. Mills, J.Q. Trojanowski, and V.M. Lee The acetylation of tau inhibits its function and promotes pathological tau aggregation Nat. Commun. 2 2011 252
46. G.M. Cole, and S.A. Frautschy Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol. Disord Drug Targets 9 2010 140 148
47. E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, A.D. Roses, J.L. Haines, and M.A. Pericak-Vance Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 261 1993 921 923
48. J.L. Cummings Alzheimer's disease N. Engl. J. Med. 351 2004 56 67
49. L.A. Cysique, and B.J. Brew Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review Neuropsychol. Rev. 19 2009 169 185
50. M.L. Daviglus, C.C. Bell, W. Berrettini, P.E. Bowen, E.S. Connolly Jr., N.J. Cox, J.M. Dunbar-Jacob, E.C. Granieri, G. Hunt, and K. McGarry National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline Ann. Intern. Med. 153 2010 176 181
51. J.J. Day, and J.D. Sweatt Epigenetic mechanisms in cognition Neuron 70 2011 813 829
52. P.L. De Jager, J.M. Shulman, L.B. Chibnik, B.T. Keenan, T. Raj, R.S. Wilson, L. Yu, S.E. Leurgans, D. Tran, C. Aubin Alzheimer's Disease Neuroimaging Initiative A genome-wide scan for common variants affecting the rate of age-related cognitive decline Neurobiol. Aging 2011 10.1016/j.neurobiolaging. 2011.09.033 Published online November 3, 2011
53. B. De Strooper, R. Vassar, and T. Golde The secretases: enzymes with therapeutic potential in Alzheimer disease Nat. Rev. Neurol. 6 2010 99 107
54. R. Deane, A. Sagare, K. Hamm, M. Parisi, S. Lane, M.B. Finn, D.M. Holtzman, and B.V. Zlokovic apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain J. Clin. Invest. 118 2008 4002 4013
55. H. Decker, K.Y. Lo, S.M. Unger, S.T. Ferreira, and M.A. Silverman Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons J. Neurosci. 30 2010 9166 9171
56. N.A. Dennis, J.N. Browndyke, J. Stokes, A. Need, J.R. Burke, K.A. Welsh-Bohmer, and R. Cabeza Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers Alzheimers Dement. 6 2010 303 311
57. C.A. Dickey, A. Kamal, K. Lundgren, N. Klosak, R.M. Bailey, J. Dunmore, P. Ash, S. Shoraka, J. Zlatkovic, and C.B. Eckman The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins J. Clin. Invest. 117 2007 648 658
58. H. Du, L. Guo, F. Fang, D. Chen, A.A. Sosunov, G.M. McKhann, Y. Yan, C. Wang, H. Zhang, and J.D. Molkentin Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease Nat. Med. 14 2008 1097 1105
59. J.A. Duce, A. Tsatsanis, M.A. Cater, S.A. James, E. Robb, K. Wikhe, S.L. Leong, K. Perez, T. Johanssen, and M.A. Greenough Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease Cell 142 2010 857 867
60. S.B. Dumanis, J.A. Tesoriero, L.W. Babus, M.T. Nguyen, J.H. Trotter, M.J. Ladu, E.J. Weeber, R.S. Turner, B. Xu, G.W. Rebeck, and H.S. Hoe ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo J. Neurosci. 29 2009 15317 15322
61. M.S. Durakoglugil, Y. Chen, C.L. White, E.T. Kavalali, and J. Herz Reelin signaling antagonizes beta-amyloid at the synapse Proc. Natl. Acad. Sci. USA 106 2009 15938 15943
62. C.G. Evans, U.K. Jinwal, L.N. Makley, C.A. Dickey, and J.E. Gestwicki Identification of dihydropyridines that reduce cellular tau levels Chem. Commun. (Camb.) 47 2011 529 531
63. L.A. Farrer, L.A. Cupples, J.L. Haines, B. Hyman, W.A. Kukull, R. Mayeux, R.H. Myers, M.A. Pericak-Vance, N. Risch, C.M. van Duijn APOE and Alzheimer Disease Meta Analysis Consortium Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis JAMA 278 1997 1349 1356
64. N. Filippini, B.J. MacIntosh, M.G. Hough, G.M. Goodwin, G.B. Frisoni, S.M. Smith, P.M. Matthews, C.F. Beckmann, and C.E. Mackay Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele Proc. Natl. Acad. Sci. USA 106 2009 7209 7214
65. A. Fischer, F. Sananbenesi, X. Wang, M. Dobbin, and L.H. Tsai Recovery of learning and memory is associated with chromatin remodelling Nature 447 2007 178 182
66. G.B. Frisoni, N.C. Fox, C.R. Jack Jr., P. Scheltens, and P.M. Thompson The clinical use of structural MRI in Alzheimer disease Nat. Rev. Neurol. 6 2010 67 77
67. D. Galimberti, and E. Scarpini Inflammation and oxidative damage in Alzheimer's disease: friend or foe? Front. Biosci. (Schol. Ed.) 3 2011 252 266
68. L. Gan, and L. Mucke Paths of convergence: sirtuins in aging and neurodegeneration Neuron 58 2008 10 14
69. E. Genin, D. Hannequin, D. Wallon, K. Sleegers, M. Hiltunen, O. Combarros, M.J. Bullido, S. Engelborghs, P. De Deyn, and C. Berr APOE and Alzheimer disease: a major gene with semi-dominant inheritance Mol. Psychiatry 16 2011 903 907
70. K. Ghosal, D.L. Vogt, M. Liang, Y. Shen, B.T. Lamb, and S.W. Pimplikar Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain Proc. Natl. Acad. Sci. USA 106 2009 18367 18372
71. P. Giannakopoulos, F.R. Herrmann, T. Bussire, C. Bouras, E. Kövari, D.P. Perl, J.H. Morrison, G. Gold, and P.R. Hof Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease Neurology 60 2003 1495 1500
72. G.E. Gibson, V. Haroutunian, H. Zhang, L.C.H. Park, Q. Shi, M. Lesser, R.C. Mohs, R.K.F. Sheu, and J.P. Blass Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype Ann. Neurol. 48 2000 297 303
73. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette, J.M. Orgogozo AN1792(QS-21)-201 Study Team Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 64 2005 1553 1562
74. M.L. Giuffrida, F. Caraci, B. Pignataro, S. Cataldo, P. De Bona, V. Bruno, G. Molinaro, G. Pappalardo, A. Messina, and A. Palmigiano Beta-amyloid monomers are neuroprotective J. Neurosci. 29 2009 10582 10587
75. T.E. Golde, L.S. Schneider, and E.H. Koo Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift Neuron 69 2011 203 213
76. T. Gómez-Isla, J.L. Price, D.W. McKeel Jr., J.C. Morris, J.H. Growdon, and B.T. Hyman Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease J. Neurosci. 16 1996 4491 4500
77. I. Gozes, A. Stewart, B. Morimoto, A. Fox, K. Sutherland, and D. Schmeche Addressing Alzheimer's disease tangles: from NAP to AL-108 Curr. Alzheimer Res. 6 2009 455 460
78. R.C. Green, L.S. Schneider, D.A. Amato, A.P. Beelen, G. Wilcock, E.A. Swabb, K.H. Zavitz Tarenflurbil Phase 3 Study Group Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA 302 2009 2557 2564
79. D. Grouselle, R. Winsky-Sommerer, J.P. David, A. Delacourte, P. Dournaud, and J. Epelbaum Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele Neurosci. Lett. 255 1998 21 24
80. T. Gura Hope in Alzheimer's fight emerges from unexpected places Nat. Med. 14 2008 894
81. M.N. Haan, L. Shemanski, W.J. Jagust, T.A. Manolio, and L. Kuller The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons JAMA 282 1999 40 46
82. H. Hampel, R. Frank, K. Broich, S.J. Teipel, R.G. Katz, J. Hardy, K. Herholz, A.L. Bokde, F. Jessen, and Y.C. Hoessler Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nat. Rev. Drug Discov. 9 2010 560 574
83. H. Harris, and D.C. Rubinsztein Control of autophagy as a therapy for neurodegenerative disease Nat. Rev. Neurol. 8 2011 108 117
84. F.M. Harris, W.J. Brecht, Q. Xu, I. Tesseur, L. Kekonius, T. Wyss-Coray, J.D. Fish, E. Masliah, P.C. Hopkins, and K. Scearce-Levie Carboxyl-terminal- truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice Proc. Natl. Acad. Sci. USA 100 2003 10966 10971
85. F.M. Harris, I. Tesseur, W.J. Brecht, Q. Xu, K. Mullendorff, S. Chang, T. Wyss-Coray, R.W. Mahley, and Y. Huang Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease J. Biol. Chem. 279 2004 3862 3868
86. J.A. Harris, N. Devidze, B. Halabisky, I. Lo, M.T. Thwin, G.Q. Yu, D.E. Bredesen, E. Masliah, and L. Mucke Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein J. Neurosci. 30 2010 372 381
87. R.E. Hartman, D.F. Wozniak, A. Nardi, J.W. Olney, L. Sartorius, and D.M. Holtzman Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology Exp. Neurol. 170 2001 326 344
88. K. Herrup Reimagining Alzheimer's disease - an age-based hypothesis J. Neurosci. 30 2010 16755 16762
89. S. Higashi, E. Iseki, R. Yamamoto, M. Minegishi, H. Hino, K. Fujisawa, T. Togo, O. Katsuse, H. Uchikado, and Y. Furukawa Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies Brain Res. 1184 2007 284 294
90. D.M. Holtzman, R.E. Pitas, J. Kilbridge, B. Nathan, R.W. Mahley, G. Bu, and A.L. Schwartz Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line Proc. Natl. Acad. Sci. USA 92 1995 9480 9484
91. D.M. Holtzman, K.R. Bales, S. Wu, P. Bhat, M. Parsadanian, A.M. Fagan, L.K. Chang, Y. Sun, and S.M. Paul Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease J. Clin. Invest. 103 1999 R15 R21
92. D.M. Holtzman, K.R. Bales, T. Tenkova, A.M. Fagan, M. Parsadanian, L.J. Sartorius, B. Mackey, J. Olney, D. McKeel, D. Wozniak, and S.M. Paul Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. USA 97 2000 2892 2897
93. B.R. Hoover, M.N. Reed, J. Su, R.D. Penrod, L.A. Kotilinek, M.K. Grant, R. Pitstick, G.A. Carlson, L.M. Lanier, and L.L. Yuan Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration Neuron 68 2010 1067 1081
94. Y. Huang Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies Curr. Opin. Drug Discov. Devel. 9 2006 627 641
95. Y. Huang Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease Trends Mol. Med. 16 2010 287 294
96. K. Iqbal, F. Liu, C.X. Gong, and I. Grundke-Iqbal Tau in Alzheimer disease and related tauopathies Curr. Alzheimer Res. 7 2010 656 664
97. M.A. Israel, S.H. Yuan, C. Bardy, S.M. Reyna, Y. Mu, C. Herrera, M.P. Hefferan, S. Van Gorp, K.L. Nazor, and F.S. Boscolo Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells Nature 482 2012 216 220
98. L.M. Ittner, and J. Götz Amyloid-β and tau - a toxic pas de deux in Alzheimer's disease Nat. Rev. Neurosci. 12 2011 65 72
99. C.R. Jack Jr., M.S. Albert, D.S. Knopman, G.M. McKhann, R.A. Sperling, M.C. Carrillo, B. Thies, and C.H. Phelps Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 7 2011 257 262
100. Z.-S. Ji, R.D. Miranda, Y.M. Newhouse, K.H. Weisgraber, Y. Huang, and R.W. Mahley Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells J. Biol. Chem. 277 2002 21821 21828
101. J. Jo, D.J. Whitcomb, K.M. Olsen, T.L. Kerrigan, S.C. Lo, G. Bru-Mercier, B. Dickinson, S. Scullion, M. Sheng, G. Collingridge, and K. Cho Aβ(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β Nat. Neurosci. 14 2011 545 547
102. P.B. Jones, K.W. Adams, A. Rozkalne, T.L. Spires-Jones, T.T. Hshieh, T. Hashimoto, C.A. von Armin, M. Mielke, B.J. Bacskai, and B.T. Hyman Apolipoprotein E: Isoform specific differences in tertiary structure and interaction with amyloid-beta in human Alzheimer brain PLoS One 6 2011 e14586
103. M. Jucker The benefits and limitations of animal models for translational research in neurodegenerative diseases Nat. Med. 16 2010 1210 1214
104. M. Jucker, and L.C. Walker Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders Ann. Neurol. 70 2011 532 540
105. E. Karran, M. Mercken, and B. De Strooper The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics Nat. Rev. Drug Discov. 10 2011 698 712
106. J. Kim, J.M. Basak, and D.M. Holtzman The role of apolipoprotein E in Alzheimer's disease Neuron 63 2009 287 303
107. S. Kim, J.R. Jensen, K. Cisek, K.E. Funk, S. Naphade, K. Schafer, and J. Kuret Imaging as a strategy for premortem diagnosis and staging of tauopathies Curr. Alzheimer Res. 7 2010 230 234
108. J. Kim, H. Jiang, S. Park, A.E. Eltorai, F.R. Stewart, H. Yoon, J.M. Basak, M.B. Finn, and D.M. Holtzman Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis J. Neurosci. 31 2011 18007 18012
109. M.T. Koh, R.P. Haberman, S. Foti, T.J. McCown, and M. Gallagher Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment Neuropsychopharmacology 35 2010 1016 1025
110. M. Koistinaho, S. Lin, X. Wu, M. Esterman, D. Koger, J. Hanson, R. Higgs, F. Liu, S. Malkani, K.R. Bales, and S.M. Paul Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides Nat. Med. 10 2004 719 726
111. P.L. Kramer, H. Xu, R.L. Woltjer, S.K. Westaway, D. Clark, D. Erten-Lyons, J.A. Kaye, K.A. Welsh-Bohmer, J.C. Troncoso, and W.R. Markesbery Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study Neurobiol. Aging 32 2011 2113 2122
112. L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, J. Harrison, C.L. Masters, S. Targum, A.I. Bush, R. Murdoch PBT2-201-EURO study group Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol. 7 2008 779 786
113. D.T. Laskowitz, S.E. McKenna, P. Song, H. Wang, L. Durham, N. Yeung, D. Christensen, and M.P. Vitek COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury J. Neurotrauma 24 2007 1093 1107
114. H.P. Lee, X. Zhu, G. Casadesus, R.J. Castellani, A. Nunomura, M.A. Smith, H.G. Lee, and G. Perry Antioxidant approaches for the treatment of Alzheimer's disease Expert Rev. Neurother. 10 2010 1201 1208
115. K.J. Lee, C.E. Moussa, Y. Lee, Y. Sung, B.W. Howell, R.S. Turner, D.T. Pak, and H.S. Hoe Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines Neuroscience 169 2010 344 356
116. G. Li, N. Bien-Ly, Y. Andrews-Zwilling, Q. Xu, A. Bernardo, K. Ring, B. Halabisky, C. Deng, R.W. Mahley, and Y. Huang GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice Cell Stem Cell 5 2009 634 645
117. S. Li, M. Jin, T. Koeglsperger, N.E. Shepardson, G.M. Shankar, and D.J. Selkoe Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors J. Neurosci. 31 2011 6627 6638
118. M.W. Logue, M. Schu, B.N. Vardarajan, J. Buros, R.C. Green, R.C. Go, P. Griffith, T.O. Obisesan, R. Shatz, A. Borenstein Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group A comprehensive genetic association study of Alzheimer disease in African Americans Arch. Neurol. 68 2011 1569 1579
119. O.L. Lopez, J.T. Becker, A.S. Wahed, J. Saxton, R.A. Sweet, D.A. Wolk, W. Klunk, and S.T. Dekosky Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease J. Neurol. Neurosurg. Psychiatry 80 2009 600 607
120. R.W. Mahley, K.H. Weisgraber, and Y. Huang Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease Proc. Natl. Acad. Sci. USA 103 2006 5644 5651
121. C. Marchetti, and H. Marie Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models? Rev. Neurosci. 22 2011 373 402
122. E. Masliah, M. Mallory, N. Ge, M. Alford, I. Veinbergs, and A.D. Roses Neurodegeneration in the central nervous system of apoE-deficient mice Exp. Neurol. 136 1995 107 122
123. E. Masliah, E. Rockenstein, I. Veinbergs, Y. Sagara, M. Mallory, M. Hashimoto, and L. Mucke β-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease Proc. Natl. Acad. Sci. USA 98 2001 12245 12250
124. E. Masliah, E. Rockenstein, A. Adame, M. Alford, L. Crews, M. Hashimoto, P. Seubert, M. Lee, J. Goldstein, and T. Chilcote Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease Neuron 46 2005 857 868
125. K.G. Mawuenyega, W. Sigurdson, V. Ovod, L. Munsell, T. Kasten, J.C. Morris, K.E. Yarasheski, and R.J. Bateman Decreased clearance of CNS beta-amyloid in Alzheimer's disease Science 330 2010 1774
126. W.J. Meilandt, G.-Q. Yu, J. Chin, E.D. Roberson, J.J. Palop, T. Wu, K. Scearce-Levie, and L. Mucke Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease J. Neurosci. 28 2008 5007 5017
127. M. Millan Sanchez, S.N. Heyn, D. Das, S. Moghadam, K.J. Martin, and A. Salehi Neurobiological elements of cognitive dysfunction in Down Syndrome: Exploring the role of APP Biol. Psychiatry 71 2011 403 409
128. J.A. Miller, S. Horvath, and D.H. Geschwind Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways Proc. Natl. Acad. Sci. USA 107 2010 12698 12703
129. J. Miller, M. Arrasate, E. Brooks, C.P. Libeu, J. Legleiter, D. Hatters, J. Curtis, K. Cheung, P. Krishnan, and S. Mitra Identifying polyglutamine protein species in situ that best predict neurodegeneration Nat. Chem. Biol. 7 2011 925 934
130. S.W. Min, S.H. Cho, Y. Zhou, S. Schroeder, V. Haroutunian, W.W. Seeley, E.J. Huang, Y. Shen, E. Masliah, and C. Mukherjee Acetylation of tau inhibits its degradation and contributes to tauopathy Neuron 67 2010 953 966
131. J.C. Morris, C.M. Roe, E.A. Grant, D. Head, M. Storandt, A.M. Goate, A.M. Fagan, D.M. Holtzman, and M.A. Mintun Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease Arch. Neurol. 66 2009 1469 1475
132. M. Morris, S. Maeda, K. Vossel, and L. Mucke The many faces of tau Neuron 70 2011 410 426
133. R.A. Nixon, and D.S. Yang Autophagy failure in Alzheimer's disease-locating the primary defect Neurobiol. Dis. 43 2011 38 45
134. J.J. Palop, and L. Mucke Epilepsy and cognitive impairments in Alzheimer disease Arch. Neurol. 66 2009 435 440
135. J.J. Palop, and L. Mucke Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks Nat. Neurosci. 13 2010 812 818
136. J.J. Palop, B. Jones, L. Kekonius, J. Chin, G.-Q. Yu, J. Raber, E. Masliah, and L. Mucke Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits Proc. Natl. Acad. Sci. USA 100 2003 9572 9577
137. J.J. Palop, J. Chin, and L. Mucke A network dysfunction perspective on neurodegenerative diseases Nature 443 2006 768 773
138. S. Peleg, F. Sananbenesi, A. Zovoilis, S. Burkhardt, S. Bahari-Javan, R.C. Agis-Balboa, P. Cota, J.L. Wittnam, A. Gogol-Doering, and L. Opitz Altered histone acetylation is associated with age-dependent memory impairment in mice Science 328 2010 753 756
139. V.H. Perry, J.A. Nicoll, and C. Holmes Microglia in neurodegenerative disease Nat. Rev. Neurol. 6 2010 193 201
140. F. Pickford, E. Masliah, M. Britschgi, K. Lucin, R. Narasimhan, P.A. Jaeger, S. Small, B. Spencer, E. Rockenstein, B. Levine, and T. Wyss-Coray The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice J. Clin. Invest. 118 2008 2190 2199
141. V.P. Prasher, M.J. Farrer, A.M. Kessling, E.M.C. Fisher, R.J. West, P.C. Barber, and A.C. Butler Molecular mapping of Alzheimer-type dementia in Down's syndrome Ann. Neurol. 43 1998 380 383
142. D. Putcha, M. Brickhouse, K. O'Keefe, C. Sullivan, D. Rentz, G. Marshall, B. Dickerson, and R. Sperling Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults J. Neurosci. 31 2011 17680 17688
143. D. Puzzo, L. Privitera, M. Fa', A. Staniszewski, G. Hashimoto, F. Aziz, M. Sakurai, E.M. Ribe, C.M. Troy, and M. Mercken Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory Ann. Neurol. 69 2011 819 830
144. H.W. Querfurth, and F.M. LaFerla Alzheimer's disease N. Engl. J. Med. 362 2010 329 344
145. J. Raber, D. Wong, M. Buttini, M. Orth, S. Bellosta, R.E. Pitas, R.W. Mahley, and L. Mucke Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females Proc. Natl. Acad. Sci. USA 95 1998 10914 10919
146. J. Raber, D. Wong, G.-Q. Yu, M. Buttini, R.W. Mahley, R.E. Pitas, and L. Mucke Apolipoprotein E and cognitive performance Nature 404 2000 352 354
147. J. Raber, G. Bongers, A. LeFevour, M. Buttini, and L. Mucke Androgens protect against apolipoprotein E4-induced cognitive deficits J. Neurosci. 22 2002 5204 5209
148. M.M. Reddy, R. Wilson, J. Wilson, S. Connell, A. Gocke, L. Hynan, D. German, and T. Kodadek Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening Cell 144 2011 132 142
149. E.M. Reiman, J.B. Langbaum, A.S. Fleisher, R.J. Caselli, K. Chen, N. Ayutyanont, Y.T. Quiroz, K.S. Kosik, F. Lopera, and P.N. Tariot Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments J. Alzheimers Dis. 26 Suppl 3 2011 321 329
150. A.M. Remes, L. Laru, H. Tuominen, S. Aalto, N. Kemppainen, H. Mononen, K. Ngren, R. Parkkola, and J.O. Rinne Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication Arch. Neurol. 65 2008 540 544
151. M. Renner, P.N. Lacor, P.T. Velasco, J. Xu, A. Contractor, W.L. Klein,
152. D.R. Riddell, H. Zhou, K. Atchison, H.K. Warwick, P.J. Atkinson, J. Jefferson, L. Xu, S. Aschmies, Y. Kirksey, and Y. Hu Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels J. Neurosci. 28 2008 11445 11453
153. R. Rönicke, M. Mikhaylova, S. Rönicke, J. Meinhardt, U.H. Schröder, M. Fändrich, G. Reiser, M.R. Kreutz, and K.G. Reymann Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-containing NMDA receptors Neurobiol. Aging 32 2011 2219 2228
154. C. Rosendorff, M.S. Beeri, and J.M. Silverman Cardiovascular risk factors for Alzheimer's disease Am. J. Geriatr. Cardiol. 16 2007 143 149
155. A. Rovelet-Lecrux, D. Hannequin, G. Raux, N. Le Meur, A. Laquerrire, A. Vital, C. Dumanchin, S. Feuillette, A. Brice, and M. Vercelletto APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy Nat. Genet. 38 2006 24 26
156. M.J. Sadowski, J. Pankiewicz, H. Scholtzova, P.D. Mehta, F. Prelli, D. Quartermain, and T. Wisniewski Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease Proc. Natl. Acad. Sci. USA 103 2006 18787 18792
157. N. Sahara, M. Murayama, T. Mizoroki, M. Urushitani, Y. Imai, R. Takahashi, S. Murata, K. Tanaka, and A. Takashima In vivo evidence of CHIP up-regulation attenuating tau aggregation J. Neurochem. 94 2005 1254 1263
158. N. Sahara, S. Maeda, Y. Yoshiike, T. Mizoroki, S. Yamashita, M. Murayama, J.M. Park, Y. Saito, S. Murayama, and A. Takashima Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain J. Neurosci. Res. 85 2007 3098 3108
159. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blennow, M. Raskind, M. Sabbagh, L.S. Honig, R. Doody, C.H. van Dyck Bapineuzumab 201 Clinical Trial Investigators A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
160. S. Salloway, R. Sperling, R. Keren, A.P. Porsteinsson, C.H. van Dyck, P.N. Tariot, S. Gilman, D. Arnold, S. Abushakra, C. Hernandez ELND005-AD201 Investigators A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease Neurology 77 2011 1253 1262
161. R.O. Sanchez-Mejia, J.W. Newman, S. Toh, G.Q. Yu, Y. Zhou, B. Halabisky, M. Cissé, K. Scearce-Levie, I.H. Cheng, and L. Gan Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease Nat. Neurosci. 11 2008 1311 1318
162. S. Sarantseva, S. Timoshenko, O. Bolshakova, E. Karaseva, D. Rodin, A.L. Schwarzman, and M.P. Vitek Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease PLoS ONE 4 2009 e8191
163. M. Sastre, J.C. Richardson, S.M. Gentleman, and D.J. Brooks Inflammatory risk factors and pathologies associated with Alzheimer's disease Curr. Alzheimer Res. 8 2011 132 141
164. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, and K. Khan Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
165. R.H. Schirmer, H. Adler, M. Pickhardt, and E. Mandelkow "Lest we forget you - methylene blue..." Neurobiol. Aging 32 2011 2325, e7-e16
166. N.F. Schor What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us Ann. Neurol. 69 2011 237 239
167. E.S. Sharp, and M. Gatz Relationship between education and dementia: an updated systematic review Alzheimer Dis. Assoc. Disord. 25 2011 289 304
168. P. Shaw, J.P. Lerch, J.C. Pruessner, K.N. Taylor, A.B. Rose, D. Greenstein, L. Clasen, A. Evans, J.L. Rapoport, and J.N. Giedd Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study Lancet Neurol. 6 2007 494 500
169. Z.H. Sheng, and Q. Cai Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration Nat. Rev. Neurosci. 13 2012 77 93
170. H. Shimada, S. Ataka, T. Tomiyama, H. Takechi, H. Mori, and T. Miki Clinical course of patients with familial early-onset Alzheimer's disease potentially lacking senile plaques bearing the E693Delta mutation in amyloid precursor protein Dement. Geriatr. Cogn. Disord. 32 2011 45 54
171. D.W. Shineman, G.S. Basi, J.L. Bizon, C.A. Colton, B.D. Greenberg, B.A. Hollister, J. Lincecum, G.G. Leblanc, L.B. Lee, and F. Luo Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies Alzheimers Res. Ther. 3 2011 28
172. S.A. Shumaker, C. Legault, S.R. Rapp, L. Thal, R.B. Wallace, J.K. Ockene, S.L. Hendrix, B.N. Jones 3rd, A.R. Assaf, R.D. Jackson WHIMS Investigators Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial JAMA 289 2003 2651 2662
173. E.M. Sigurdsson Tau-focused immunotherapy for Alzheimer's disease and related tauopathies Curr. Alzheimer Res. 6 2009 446 450
174. A.M. Simón, L. Schiapparelli, P. Salazar-Colocho, M. Cuadrado-Tejedor, L. Escribano, R. López de Maturana, J. Del Río, A. Pérez-Mediavilla, and D. Frechilla Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Abeta levels Neurobiol. Dis. 33 2009 369 378
175. G.W. Small, L.M. Ercoli, D.H.S. Silverman, S.C. Huang, S. Komo, S.Y. Bookheimer, H. Lavretsky, K. Miller, P. Siddarth, and N.L. Rasgon Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease Proc. Natl. Acad. Sci. USA 97 2000 6037 6042
176. R.A. Sperling, B.C. Dickerson, M. Pihlajamaki, P. Vannini, P.S. LaViolette, O.V. Vitolo, T. Hedden, J.A. Becker, D.M. Rentz, D.J. Selkoe, and K.A. Johnson Functional alterations in memory networks in early Alzheimer's disease Neuromolecular Med. 12 2010 27 43
177. R.A. Sperling, C.R. Jack Jr., S.E. Black, M.P. Frosch, S.M. Greenberg, B.T. Hyman, P. Scheltens, M.C. Carrillo, W. Thies, and M.M. Bednar Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup Alzheimers Dement. 7 2011 367 385
178. V. Srikanth, A. Maczurek, T. Phan, M. Steele, B. Westcott, D. Juskiw, and G. Münch Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease Neurobiol. Aging 32 2011 763 777
179. S. Taniguchi, N. Suzuki, M. Masuda, S. Hisanaga, T. Iwatsubo, M. Goedert, and M. Hasegawa Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins J. Biol. Chem. 280 2005 7614 7623
180. T. Tomiyama, S. Matsuyama, H. Iso, T. Umeda, H. Takuma, K. Ohnishi, K. Ishibashi, R. Teraoka, N. Sakama, and T. Yamashita A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo J. Neurosci. 30 2010 4845 4856
181. C. Van Den Heuvel, E. Thornton, and R. Vink Traumatic brain injury and Alzheimer's disease: a review Prog. Brain Res. 161 2007 303 316
182. S. Vepsäläinen, S. Helisalmi, A.M. Koivisto, T. Tapaninen, M. Hiltunen, and H. Soininen Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients J. Neurol. 254 2007 1504 1508
183. L. Verret, E.O. Mann, G.B. Hang, A.M.I. Barth, I. Cobos, K. Ho, N. Devidze, E. Masliah, A.C. Kreitzer, and I. Mody Key role of interneuronal impairments in Alzheimer's disease-related neural network and cognitive dysfunction Cell 149 2012 10.1016/j.cell.2012.02.046 Published online April 26, 2012
184. S.A. Villeda, J. Luo, K.I. Mosher, B. Zou, M. Britschgi, G. Bieri, T.M. Stan, N. Fainberg, Z. Ding, and A. Eggel The ageing systemic milieu negatively regulates neurogenesis and cognitive function Nature 477 2011 90 94
185. V.L. Villemagne, S. Ataka, T. Mizuno, W.S. Brooks, Y. Wada, M. Kondo, G. Jones, Y. Watanabe, R. Mulligan, and M. Nakagawa High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types Arch. Neurol. 66 2009 1537 1544
186. K.A. Vossel, K. Zhang, J. Brodbeck, A.C. Daub, P. Sharma, S. Finkbeiner, B. Cui, and L. Mucke Tau reduction prevents Abeta-induced defects in axonal transport Science 330 2010 198
187. K. Vossel, N. Bien-Ly, A. Bernardo, K. Rascovsky, A. Karydas, G. Rabinovici, M. Sidhu, E. Huang, B. Miller, and Y. Huang ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease Neurocase 2012 10.1080/13554794.2012.667124
188. I. Vulih-Shultzman, A. Pinhasov, S. Mandel, N. Grigoriadis, O. Touloumi, Z. Pittel, and I. Gozes Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model J. Pharmacol. Exp. Ther. 323 2007 438 449
189. S.W. Weyer, M. Klevanski, A. Delekate, V. Voikar, D. Aydin, M. Hick, M. Filippov, N. Drost, K.L. Schaller, and M. Saar APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP EMBO J. 30 2011 2266 2280
190. A. Wimo, and M. Prince World Alzheimer Report 2010: The Global Economic Impact of Dementia 2010 Alzheimer's Disease International London pp. 1-56
191. B. Winner, R. Jappelli, S.K. Maji, P.A. Desplats, L. Boyer, S. Aigner, C. Hetzer, T. Loher, M. Vilar, and S. Campioni In vivo demonstration that alpha-synuclein oligomers are toxic Proc. Natl. Acad. Sci. USA 108 2011 4194 4199
192. J. Wu, R.S. Petralia, H. Kurushima, H. Patel, M.Y. Jung, L. Volk, S. Chowdhury, J.D. Shepherd, M. Dehoff, and Y. Li Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β-amyloid generation Cell 147 2011 615 628
193. Q. Xu, A. Bernardo, D. Walker, T. Kanegawa, R.W. Mahley, and Y. Huang Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus J. Neurosci. 26 2006 4985 4994
194. Q. Xu, D. Walker, A. Bernardo, J. Brodbeck, M.E. Balestra, and Y. Huang Intron-3 retention/splicing controls neuronal expression of apolipoprotein E in the CNS J. Neurosci. 28 2008 1452 1459
195. L. Yang, Z. Wang, B. Wang, N.J. Justice, and H. Zheng Amyloid precursor protein regulates Cav1.2 L-type calcium channel levels and function to influence GABAergic short-term plasticity J. Neurosci. 29 2009 15660 15668
196. D.S. Yang, P. Stavrides, P.S. Mohan, S. Kaushik, A. Kumar, M. Ohno, S.D. Schmidt, D.W. Wesson, U. Bandyopadhyay, and Y. Jiang Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis Autophagy 7 2011 788 789
197. J. Yang, Y. Ji, P. Mehta, K.A. Bates, Y. Sun, and T. Wisniewski Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice J. Alzheimers Dis. 24 2011 269 285
198. S. Ye, Y. Huang, K. Müllendorff, L. Dong, G. Giedt, E.C. Meng, F.E. Cohen, I.D. Kuntz, K.H. Weisgraber, and R.W. Mahley Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target Proc. Natl. Acad. Sci. USA 102 2005 18700 18705
199. K.R. Zahs, and K.H. Ashe 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci. 33 2010 381 389
200. H. Zempel, E. Thies, E. Mandelkow, and E.M. Mandelkow Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines J. Neurosci. 30 2010 11938 11950
201. B. Zhang, A. Maiti, S. Shively, F. Lakhani, G. McDonald-Jones, J. Bruce, E.B. Lee, S.X. Xie, S. Joyce, and C. Li Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model Proc. Natl. Acad. Sci. USA 102 2005 227 231
202. N. Zhong, and K.H. Weisgraber Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure J. Biol. Chem. 284 2009 6027 6031